The differentiation syndrome in patients with acute promyelocytic leukemia: Experience of the pethema group and review of the literature

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages

  Montesinos, Pau ^a   Sanz, Miguel A ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864943591     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.059     Document Type: Review

References (41)

1. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell R. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292. PMid:1637024
2. Luesink M, Pennings JL, Wissink WM, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood 2009; 114:5512. http://dx.doi.org/10.1182/blood-2009-02- 204834 PMid:19828696
3. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994; 120:278. PMid:8291820
4. Nicolls MR, Terada LS, Tuder RM, et al. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Am J Respir Crit Care Med 1998; 158:1302. PMid:9769296
5. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90:1014-1021. PMid:9242531
6. De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndromes in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood. 1998;92:2712-2718. PMid:9763554
7. De Botton S, Chevret S, Coiteux V, et al. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia. 2003;17:339-342. http://dx.doi.org/10.1038/sj.leu.2402807 PMid:12592333
8. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95:90-95. PMid:10607690
9. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113:775. http://dx.doi.org/10.1182/blood-2008-07-168617 PMid:18945964
10. Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.Blood. 2010 Jun 24;115(25):5137-46. http://dx.doi.org/10.1182/blood-2010-01-266007 PMid:20393132
11. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994;84:3843-3849. PMid:7949141
12. Jung JI, Choi JE, Hahn ST, et al. Radiologic features of all-transretinoic acid syndrome. AJR Am J Roentgenol 2002; 178:475. PMid:11804921
13. Flombaum CD, Isaacs M, Reich L, et al. Acute renal failure associated with the retinoic acid syndrome in acute promyelocytic leukemia. Am J Kidney Dis 1996; 27:134. http://dx.doi.org/10.1016/S0272-6386(96)90041-4
14. Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18:2620. PMid:10893295
15. Raanani P, Segal E, Levi I, et al. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA--a manifestation of the basic disease or the treatment. Leuk Lymphoma 2000; 37:605. http://dx.doi.org/10.3109/10428190009058513
16. De Santis GC, Madeira MI, de Oliveira LC, Falcao RP, Rego EM. Cardiac stunning as a manifestation of ATRA differentiation syndrome in acute promyelocytic leukemia. Med Oncol. 2011 Jan 26.
17. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995 Mar 1;85(5):1202-6. PMid:7858250
18. Cortes JE, Kantarjian H, O'Brien S, et al.All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer. 1994 Jun 15;73(12):2946- 52. http://dx.doi.org/10.1002/1097- 0142(19940615)73:12<2946::AID-CNCR2820731211>3.0.CO;2- Q
19. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996 Aug 15;88(4):1390-8. PMid:8695858
20. Mathews V, George B, Chendamarai E, Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data. JCO 2010 August 15; 28(24): 3866-3871 http://dx.doi.org/10.1200/JCO.2010.28.5031 PMid:20644086
21. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011 Jul 10;29(20):2753-7. http://dx.doi.org/10.1200/JCO.2010.32.2107 PMid:21646615
22. Liu YF, Shen ZX, Chen X, et al. Clinical observation of the shortterm efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL). Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):25-7. PMid:12679006
23. Ravandi F, Estey E, Jones D, et al. ffective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27:504-510. http://dx.doi.org/10.1200/JCO.2008.18.6130 PMid:19075265
24. Lengfelder E, Lo-Coco F, Montesinos P, et al. Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL ASH Annual Meeting Abstracts 2010 116:15
25. Adès L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Group. J Clin Oncol. 2006;24:5703-5710. http://dx.doi.org/10.1200/JCO.2006.08.1596 PMid:17116939
26. Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with alltrans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia-German AML Cooperative Group. Leukemia. 2000;14:1362-1370. http://dx.doi.org/10.1038/sj.leu.2401843 PMid:10942230
27. Wu JJ, Cantor A, Moscinski LC. Beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid. Leuk Res. 2007;31:49-57. http://dx.doi.org/10.1016/j.leukres.2006.04.012 PMid:16764927
28. Cunha De Santis G, Tamarozzi MB, et al. Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica. 2007;92:1615-22. http://dx.doi.org/10.3324/haematol.10607 PMid:18055984
29. Jeddi R, Ghédira H, Mnif S, et al. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res 2010; 34:545. http://dx.doi.org/10.1016/j.leukres.2009.09.017 PMid:19800119
30. de la Serna J, Montesinos P, Vellenga E, et al: Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395-3402, 2008 http://dx.doi.org/10.1182/blood-2007-07-100669 PMid:18195095
31. Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J Clin Pharm Ther 2008; 33:331. http://dx.doi.org/10.1111/j.1365- 2710.2008.00935.x PMid:18613850
32. Thepot S, Gardin C, Chevret S, et al, Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL. ASH Annual Meeting Abstracts 2008 112:139
33. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875. http://dx.doi.org/10.1182/blood-2008-04-150250 PMid:18812465
34. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia. 1995;9:774-778. PMid:7769839
35. Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78:213-219. http://dx.doi.org/10.1111/j.1600-0609.2006.00803.x PMid:17241371
36. Larson RS, Brown DC, Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood. 1997;90:2747-2756. PMid:9326242
37. Di Noto R, Schiavone EM, Ferrara F et al. All-trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid blast cells. Brit J Haematol. 1996;88:247-255. http://dx.doi.org/10.1111/j.1365-2141.1994.tb05014.x PMid:7803267
38. Tallman MS, Lefèbvre P, Baine RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost. 2004;2:1341-1350. http://dx.doi.org/10.1111/j.1538-7836.2004.00787.x PMid:15304040
39. Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:463-482. http://dx.doi.org/10.1016/S1521-6926(03)00059-8
40. Ko BS, Tang JL, Chen YC, Yao Met al. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia-the occurrence of retinoic acid syndrome is a risk factor. Leukemia. 1999;13:1406-1408. http://dx.doi.org/10.1038/sj.leu.2401495 PMid:10482992
41. Montesinos P, Díaz-Mediavilla J, Debén G, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 2009 Sep;94(9):1242-9. http://dx.doi.org/10.3324/haematol.2009.007872 PMid:19608685 PMCid:2738716